OcrV1, Main, Exploration, bibRecord, 000D00

Twelve-Month Persistency of a Novel Ribose-Cross-linked Collagen Dermal Filler

Identifieur interne : 000D00 ( Main/Exploration ); précédent : 000C99; suivant : 000D01

Twelve-Month Persistency of a Novel Ribose-Cross-linked Collagen Dermal Filler

Auteurs : Rhoda S. Narins [États-Unis] ; Fredric S. Brandt [États-Unis] ; Z. Paul Lorenc [États-Unis] ; Corey S. Maas [États-Unis] ; Gary D. Monheit [États-Unis] ; Stacy R. Smith [États-Unis]

Source :

Dermatologic surgery [ 1076-0512 ] ; 2008.

RBID : Pascal:08-0362018

Descripteurs français

Pascal (Inist)
- Chirurgie, Ribose, Collagène, Derme, Dermatologie, Traitement.
Wicri :
- topic : Chirurgie.

English descriptors

KwdEn :
- Collagen, Derm, Dermatology, Ribose, Surgery, Treatment.

Abstract

BACKGROUND The porcine collagen-derived dermal filler Dermicol-P35 (Evolence, Colbar LifeScience Ltd, Herzliya, Israel) has low immunogenicity and the potential to provide a long-lasting corrective response for soft-tissue contour deficiencies and deformities. OBJECTIVE The objective was to assess the persistence of the corrective response with Dermicol-P35 up to 12 months after obtaining an optimal cosmetic result (OCR) in a randomized, multicenter study comparing the efficacy and safety of Dermicol-P35 with the hyaluronic acid (HA) filler Restylane (Medicis Pharmaceutical Co.). METHODS & MATERIALS Subjects with moderate to deep nasolabial wrinkles (n= 149) were randomized to injections of either Dermicol-P35 or HA on one side of the face and the alternative preparation on the contralateral side. If necessary, one touch-up injection could be given after 2 weeks to obtain an OCR. RESULTS Although the mean Modified Fitzpatrick Wrinkle Scale score increased gradually after achieving the OCR with Dermicol-P35, 95.3 and 76.5% of subjects, respectively, met the criteria for persistence of the corrective response after 9 and 12 months. Persistency rates were similar regardless of the requirement for a touch-up injection at Week 2. No unexpected, severe, or serious injection-related adverse events were experienced. CONCLUSION The effectiveness of Dermicol-P35 appears to be maintained for up to 1 year after achieving an OCR, both for touch-up and for non-touch-up subjects.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000275
to stream PascalFrancis, to step Curation: 000509
to stream PascalFrancis, to step Checkpoint: 000222
to stream Main, to step Merge: 000D12
to stream Main, to step Curation: 000D00

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Twelve-Month Persistency of a Novel Ribose-Cross-linked Collagen Dermal Filler</title>
<author><name sortKey="Narins, Rhoda S" sort="Narins, Rhoda S" uniqKey="Narins R" first="Rhoda S." last="Narins">Rhoda S. Narins</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Dermatology Surgery and Laser Center of NY</s1>
<s2>White Plains, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brandt, Fredric S" sort="Brandt, Fredric S" uniqKey="Brandt F" first="Fredric S." last="Brandt">Fredric S. Brandt</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>fredric S. Brandt Dermatology Research Institute</s1>
<s2>Coral Gables, Florida</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lorenc, Z Paul" sort="Lorenc, Z Paul" uniqKey="Lorenc Z" first="Z. Paul" last="Lorenc">Z. Paul Lorenc</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Lorenc Aesthetic Plastic Surgery</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Maas, Corey S" sort="Maas, Corey S" uniqKey="Maas C" first="Corey S." last="Maas">Corey S. Maas</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>The Maas Clinic</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Monheit, Gary D" sort="Monheit, Gary D" uniqKey="Monheit G" first="Gary D." last="Monheit">Gary D. Monheit</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Total Skin and Beauty Dermatology Center</s1>
<s2>Birmingham, Alabama</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Alabama</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Stacy R" sort="Smith, Stacy R" uniqKey="Smith S" first="Stacy R." last="Smith">Stacy R. Smith</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Therapeutics Clinical Research</s1>
<s2>San Diego, California</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0362018</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0362018 INIST</idno>
<idno type="RBID">Pascal:08-0362018</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000275</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000509</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000222</idno>
<idno type="wicri:doubleKey">1076-0512:2008:Narins R:twelve:month:persistency</idno>
<idno type="wicri:Area/Main/Merge">000D12</idno>
<idno type="wicri:Area/Main/Curation">000D00</idno>
<idno type="wicri:Area/Main/Exploration">000D00</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Twelve-Month Persistency of a Novel Ribose-Cross-linked Collagen Dermal Filler</title>
<author><name sortKey="Narins, Rhoda S" sort="Narins, Rhoda S" uniqKey="Narins R" first="Rhoda S." last="Narins">Rhoda S. Narins</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Dermatology Surgery and Laser Center of NY</s1>
<s2>White Plains, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brandt, Fredric S" sort="Brandt, Fredric S" uniqKey="Brandt F" first="Fredric S." last="Brandt">Fredric S. Brandt</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>fredric S. Brandt Dermatology Research Institute</s1>
<s2>Coral Gables, Florida</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lorenc, Z Paul" sort="Lorenc, Z Paul" uniqKey="Lorenc Z" first="Z. Paul" last="Lorenc">Z. Paul Lorenc</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Lorenc Aesthetic Plastic Surgery</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Maas, Corey S" sort="Maas, Corey S" uniqKey="Maas C" first="Corey S." last="Maas">Corey S. Maas</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>The Maas Clinic</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Monheit, Gary D" sort="Monheit, Gary D" uniqKey="Monheit G" first="Gary D." last="Monheit">Gary D. Monheit</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Total Skin and Beauty Dermatology Center</s1>
<s2>Birmingham, Alabama</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Alabama</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Stacy R" sort="Smith, Stacy R" uniqKey="Smith S" first="Stacy R." last="Smith">Stacy R. Smith</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Therapeutics Clinical Research</s1>
<s2>San Diego, California</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Dermatologic surgery</title>
<title level="j" type="abbreviated">Dermatol. surg.</title>
<idno type="ISSN">1076-0512</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Dermatologic surgery</title>
<title level="j" type="abbreviated">Dermatol. surg.</title>
<idno type="ISSN">1076-0512</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Collagen</term>
<term>Derm</term>
<term>Dermatology</term>
<term>Ribose</term>
<term>Surgery</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Chirurgie</term>
<term>Ribose</term>
<term>Collagène</term>
<term>Derme</term>
<term>Dermatologie</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Chirurgie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">BACKGROUND The porcine collagen-derived dermal filler Dermicol-P35 (Evolence, Colbar LifeScience Ltd, Herzliya, Israel) has low immunogenicity and the potential to provide a long-lasting corrective response for soft-tissue contour deficiencies and deformities. OBJECTIVE The objective was to assess the persistence of the corrective response with Dermicol-P35 up to 12 months after obtaining an optimal cosmetic result (OCR) in a randomized, multicenter study comparing the efficacy and safety of Dermicol-P35 with the hyaluronic acid (HA) filler Restylane (Medicis Pharmaceutical Co.). METHODS & MATERIALS Subjects with moderate to deep nasolabial wrinkles (n= 149) were randomized to injections of either Dermicol-P35 or HA on one side of the face and the alternative preparation on the contralateral side. If necessary, one touch-up injection could be given after 2 weeks to obtain an OCR. RESULTS Although the mean Modified Fitzpatrick Wrinkle Scale score increased gradually after achieving the OCR with Dermicol-P35, 95.3 and 76.5% of subjects, respectively, met the criteria for persistence of the corrective response after 9 and 12 months. Persistency rates were similar regardless of the requirement for a touch-up injection at Week 2. No unexpected, severe, or serious injection-related adverse events were experienced. CONCLUSION The effectiveness of Dermicol-P35 appears to be maintained for up to 1 year after achieving an OCR, both for touch-up and for non-touch-up subjects.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Alabama</li>
<li>Californie</li>
<li>Floride</li>
<li>État de New York</li>
</region>
</list>
<tree><country name="États-Unis"><region name="État de New York"><name sortKey="Narins, Rhoda S" sort="Narins, Rhoda S" uniqKey="Narins R" first="Rhoda S." last="Narins">Rhoda S. Narins</name>
</region>
<name sortKey="Brandt, Fredric S" sort="Brandt, Fredric S" uniqKey="Brandt F" first="Fredric S." last="Brandt">Fredric S. Brandt</name>
<name sortKey="Lorenc, Z Paul" sort="Lorenc, Z Paul" uniqKey="Lorenc Z" first="Z. Paul" last="Lorenc">Z. Paul Lorenc</name>
<name sortKey="Maas, Corey S" sort="Maas, Corey S" uniqKey="Maas C" first="Corey S." last="Maas">Corey S. Maas</name>
<name sortKey="Monheit, Gary D" sort="Monheit, Gary D" uniqKey="Monheit G" first="Gary D." last="Monheit">Gary D. Monheit</name>
<name sortKey="Smith, Stacy R" sort="Smith, Stacy R" uniqKey="Smith S" first="Stacy R." last="Smith">Stacy R. Smith</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Ticri/CIDE/explor/OcrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D00 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D00 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Ticri/CIDE
   |area=    OcrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:08-0362018
   |texte=   Twelve-Month Persistency of a Novel Ribose-Cross-linked Collagen Dermal Filler
}}

This area was generated with Dilib version V0.6.32.
Data generation: Sat Nov 11 16:53:45 2017. Site generation: Mon Mar 11 23:15:16 2024

	Serveur d'exploration sur l'OCR
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'OCR

Twelve-Month Persistency of a Novel Ribose-Cross-linked Collagen Dermal Filler

Twelve-Month Persistency of a Novel Ribose-Cross-linked Collagen Dermal Filler

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri